Ovarian Reserve Screening Across Reproductive Lifespans

Abstract

Ovarian reserve screening is a critical aspect of reproductive medicine, providing essential information about a woman's fertility potential throughout her reproductive lifespan. This review synthesizes current evidence regarding the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, and management approaches related to ovarian reserve. Emphasis is placed on recent guideline recommendations, emerging biomarkers, and practical considerations for clinical application. The article aims to equip healthcare professionals with a comprehensive, mechanism-based understanding to optimize patient counseling and individualized care.

Introduction

Assessment of ovarian reserve is foundational in reproductive endocrinology and infertility practice. With increasing trends in delayed childbearing and higher prevalence of subfertility, timely and accurate evaluation of ovarian reserve has become paramount. Ovarian reserve reflects the functional capacity of the ovaries, encompassing both the quantity and quality of primordial follicles remaining. This assessment aids in prognostication, guiding fertility treatment, and informing patient decisions regarding family planning, fertility preservation, and management of reproductive disorders. Despite significant advances, the clinical application of ovarian reserve testing must be contextualized within individual patient profiles and evolving guidelines.

Epidemiology / Disease Burden

Globally, diminished ovarian reserve (DOR) is recognized as a significant contributor to female infertility, with prevalence estimates ranging from 10% to 30% among women undergoing fertility evaluations. The burden of age-related decline in ovarian reserve is particularly pronounced in developed countries, where societal trends favor delayed childbearing. Furthermore, iatrogenic factors, such as gonadotoxic therapies and pelvic surgeries, contribute to increasing rates of DOR across various age groups. The public health implications are substantial, as DOR is intricately linked to reduced fecundity, increased time to pregnancy, and poorer outcomes in assisted reproductive technologies (ART).

Pathophysiology

Ovarian reserve is determined during fetal development, when the maximum pool of primordial follicles is established. Thereafter, a continuous, age-dependent decline ensues due to follicular atresia and ovulation. The pathophysiological basis of DOR involves both accelerated depletion and defective recruitment of follicles. Mechanistic insights reveal that oxidative stress, mitochondrial dysfunction, genetic predisposition, and autoimmune processes may exacerbate follicular loss or dysfunction. Key molecular regulators include anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B, which orchestrate the dynamic interplay of oocyte maturation and ovarian responsiveness.

Risk Factors

Numerous risk factors are implicated in the development and progression of diminished ovarian reserve. Advancing chronological age remains the most significant determinant. Other contributory factors include genetic abnormalities (e.g., Fragile X premutation, Turner syndrome), environmental exposures (e.g., smoking, chemotherapy, radiation), surgical interventions (e.g., oophorectomy, endometrioma excision), and autoimmune conditions (e.g., thyroiditis, Addison's disease). Certain lifestyle factors, such as low body mass index, excessive exercise, and chronic stress, may also influence ovarian reserve. Early identification of at-risk populations enables tailored counseling and timely intervention.

Clinical Features

Diminished ovarian reserve is frequently asymptomatic in its early stages, underscoring the importance of proactive screening in selected cohorts. Clinical presentation may include menstrual cycle irregularities, shortened menstrual intervals, or secondary infertility. In ART settings, patients with DOR often exhibit poor ovarian response to stimulation, resulting in lower oocyte yield and suboptimal embryo quality. Importantly, DOR may coexist with other reproductive endocrine disorders (e.g., polycystic ovary syndrome, premature ovarian insufficiency), complicating the clinical picture and necessitating comprehensive evaluation.

Diagnosis

Diagnostic evaluation of ovarian reserve integrates clinical risk assessment with a panel of biochemical and ultrasound-based markers. Key tests include serum AMH, basal FSH and estradiol (measured on cycle days 2–5), and antral follicle count (AFC) via transvaginal ultrasonography. AMH is considered the most reliable single marker, reflecting the pool of growing follicles and exhibiting minimal cycle variability. Elevated basal FSH and low AFC are indicative of reduced reserve, but should be interpreted in conjunction with patient age and clinical context. Emerging biomarkers, such as inhibin B and ovarian volume, are under investigation for enhanced predictive accuracy. Genetic testing may be warranted in cases suggestive of syndromic or familial DOR.

Treatment & Management

Management strategies for diminished ovarian reserve are multifaceted and individualized. For women desiring fertility, expedited referral to reproductive specialists and consideration of ART most commonly in vitro fertilization (IVF) is recommended. Modified ovarian stimulation protocols (e.g., use of higher gonadotropin doses, antagonist cycles, or adjuvant therapies such as growth hormone and androgens) may improve oocyte yield in poor responders. Fertility preservation, via oocyte or embryo cryopreservation, should be discussed with women at risk of iatrogenic or premature loss. Hormone replacement therapy may be indicated for symptomatic women with premature ovarian insufficiency. Patient education, psychological support, and multidisciplinary collaboration are essential components of comprehensive care.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in ovarian reserve assessment and management. Automated, standardized AMH assays offer improved reliability for longitudinal monitoring. Molecular profiling, including evaluation of mitochondrial DNA in cumulus cells and oocyte spindle imaging, are promising research avenues. Platelet-rich plasma (PRP) ovarian infusion and stem cell therapies are under investigation for their potential to rejuvenate ovarian function, though robust clinical evidence remains limited. Advances in ART such as preimplantation genetic testing, time-lapse embryo monitoring, and personalized stimulation protocols are refining outcomes for women with DOR. Ongoing clinical trials will further elucidate the safety and efficacy of these emerging interventions.

Guideline Recommendations

Major professional societies, including the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE), recommend ovarian reserve assessment in women at risk of infertility, prior to ART, and before gonadotoxic therapies. Routine screening in the general asymptomatic population is not currently advocated due to insufficient evidence of benefit. Clinicians are urged to interpret ovarian reserve markers within the broader clinical context, incorporating patient age, reproductive goals, and comorbidities. Shared decision-making and individualized care planning are emphasized. Ongoing updates to clinical guidelines reflect the rapidly evolving landscape of ovarian reserve research and practice.

Conclusion

Ovarian reserve screening represents a cornerstone of reproductive medicine, with vital implications for fertility prognosis, treatment planning, and patient counseling. Recent advances in biomarker development and ART have enhanced the precision and utility of ovarian reserve assessment. However, optimal clinical application requires nuanced interpretation of test results, integration with patient-specific factors, and adherence to evidence-based guidelines. Continued research into molecular mechanisms and novel therapeutics holds promise for further improving reproductive care across the lifespan.